Early immunotherapy aids in treating potentially fatal fungal pneumonias in preclinical models

Article excerpt

Researchers at UT MD Anderson found that giving immunotherapy drugs alongside standard antifungal treatments improved outcomes in preclinical models of deadly fungal lung infections. The combination approach reversed the immune system shutdown that these infections typically trigger. The findings could reshape how doctors treat invasive fungal pneumonias, which hit immunocompromised cancer patients especially hard, a population with few effective options today.